BRIEF published on 09/25/2024 at 15:05, 1 year 2 months ago GEN Reports Positive Phase 2 Trial Results for GN-037 Topical Cream Clinical Efficacy Phase 2 Trial Results GN-037 Topical Cream Plaque Psoriasis Treatment GEN Pharmaceuticals
BRIEF published on 09/25/2024 at 15:05, 1 year 2 months ago GEN annonce des résultats positifs de l'essai de phase 2 pour la crème topique GN-037 Efficacité Clinique Résultats De L'essai De Phase 2 Crème Topique GN-037 Traitement Du Psoriasis En Plaques GEN Pharmaceutique
PRESS RELEASE published on 09/25/2024 at 15:00, 1 year 2 months ago GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis GEN Pharmaceuticals announces positive Phase 2 trial results for GN-037 topical cream in treating plaque psoriasis, presented at EADV Congress 2024 Phase 2 Trial GN-037 Topical Cream GEN Pharmaceuticals Plaque Psoriasis EADV Congress
Published on 12/05/2025 at 02:35, 4 hours 55 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 30 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 25 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 30 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 29 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 59 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 39 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 4 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 15 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 15 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 30 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 30 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 45 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 45 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
